HCW Biologics Inc. (HCWB)
Nasdaq · Healthcare · Biotechnology
$1.64−3.24%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.7M
- 52-week range
- $1.50 – $29.28
- 52-week change
- −93.05%
- EPS (trailing)
- −$19.84
- Analyst rating
- 2.0 Buy
Fiscal year to Dec 2025
- Revenue
- $54K (−97.89%)
- Net income
- −$8.0M
- Operating margin
- −24271.6%
- Diluted EPS
- −$10.63
- Free cash flow
- −$13.4M
From the company’s annual report on SEC EDGAR.
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Headquarters: Miramar, United States · 35 employees · hcwbiologics.com